Maia Biotechnology Stock Investor Sentiment
| MAIA Stock | USD 2.00 0.01 0.50% |
About 61% of MAIA Biotechnology's investor base is looking to short. The analysis of the overall investor sentiment regarding MAIA Biotechnology suggests that many traders are alarmed. The current market sentiment, together with MAIA Biotechnology's historical and current headlines, can help investors time the market. In addition, many technical investors use MAIA Biotechnology stock news signals to limit their universe of possible portfolio assets.
MAIA |
MAIA Biotechnology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards MAIA Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about MAIA Biotechnology that are available to investors today. That information is available publicly through MAIA media outlets and privately through word of mouth or via MAIA internal channels. However, regardless of the origin, that massive amount of MAIA data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MAIA Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MAIA Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MAIA Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MAIA Biotechnology alpha.
MAIA Biotechnology Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Theagene Jean-manasse of 7232 shares of MAIA Biotechnology at 2.81 subject to Rule 16b-3 | 09/30/2024 |
2 | MAIA Stock Earnings MAIA Biotechnology Misses EPS for Q2 2024 - MSN | 10/04/2024 |
3 | MAIA Biotechnology Announces 2.44 Million Private Placement - StockTitan | 10/28/2024 |
4 | Acquisition by Smith Stan of 100000 shares of MAIA Biotechnology at 2.259 subject to Rule 16b-3 | 11/01/2024 |
5 | Maia Biotechnology director Steven Chaouki buys 55,553 in shares | 11/04/2024 |
6 | Director Steven Chaouki Acquires 22,133 Shares of MAIA Biotechnology Inc | 11/05/2024 |
7 | MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement | 11/07/2024 |
8 | Acquisition by Vitoc Vlad of 19982 shares of MAIA Biotechnology at 1.8 subject to Rule 16b-3 | 11/15/2024 |
9 | Acquisition by Chaouki Steven M of 34641 shares of MAIA Biotechnology at 1.17 subject to Rule 16b-3 | 11/27/2024 |
10 | MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer | 12/03/2024 |
11 | Acquisition by Guerrero Ramiro of 53418 shares of MAIA Biotechnology at 2.08 subject to Rule 16b-3 | 12/13/2024 |
Complementary Tools for MAIA Stock analysis
When running MAIA Biotechnology's price analysis, check to measure MAIA Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MAIA Biotechnology is operating at the current time. Most of MAIA Biotechnology's value examination focuses on studying past and present price action to predict the probability of MAIA Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MAIA Biotechnology's price. Additionally, you may evaluate how the addition of MAIA Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |